Dr. Slack is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10460 N 92nd St Ste 300
Scottsdale, AZ 85258Phone+1 480-323-1573
Summary
- Dr. James Slack is a hematologist in Scottsdale, AZ and is affiliated with Cancer Treatment Centers of America. He received his medical degree from University of New Mexico School of Medicine and has been in practice 34 years. He specializes in malignant hematology and cellular therapy, including stem cell transplant (autologous and allogeneic), and CAR-T cell therapy.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1985 - 1989
University of MinnesotaResidency, Internal Medicine, 1984 - 1986
University of New Mexico School of MedicineClass of 1983- University of WashingtonFellowship, Medical Oncology
Certifications & Licensure
AZ State Medical License 2003 - 2026
MN State Medical License 2021 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:Arizona State Castle Connolly, 2013
Publications & Presentations
PubMed
- 920 citationsDurable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLCourtney D. DiNardo, Eytan M. Stein, S. de Botton, Gail J. Roboz, Jessica K. Altman
The New England Journal of Medicine. 2018-06-02 - 102 citationsFinancial burden in recipients of allogeneic hematopoietic cell transplantation.Nandita Khera, Yu-hui Chang, Shahrukh K. Hashmi, James L. Slack, Timothy J. Beebe
Biology of Blood and Marrow Transplantation. 2014-09-01 - 1192 citationsDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.Hagop Kantarjian, J. Issa, Craig S. Rosenfeld, John M. Bennett, Maher Albitar
Cancer. 2006-04-15
Journal Articles
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLDaniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
Professional Memberships
- Member
- Member
- American Society for Transplantation and Cellular TherapyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
